As of Nov 18, 2026, 0 of 2 active firms rate TRAW a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
TRAW EPS & revenue forecast
EPS · NEXT QUARTER
$-0.29
Range $-0.29 – $-0.29 · 1 analysts · -48% YoY
Next period, 1 analysts expect Traws Pharma Inc to earn $-0.29 a share (range $-0.29 – $-0.29), versus $-0.55 a year earlier. Full-year consensus is $-1.33, growing to $-1.88 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Traws Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on TRAW.
#1
BF
Brandon Folkes
HC Wainwright & Co. · Rank #402
Neutral
$1.00+328.6% to target
Overall win rate
38%
+ Follow
#2
KD
Kevin DeGeeter
Ladenburg Thalmann
Neutral
No targeton TRAW
Coverage
—
+ Follow
TRAW stock forecast FAQ
What is TRAW's average 12-month price target?+
The 1 active firms with a live target average $1.00 for Traws Pharma Inc over the next 12 months, ranging from a $1.00 high to a $1.00 low, as of Nov 18, 2026.
Is TRAW stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 18, 2026, 0 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover TRAW?+
2 active firms have a recognized rating on Traws Pharma Inc as of Nov 18, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering TRAW?+
Among analysts who currently cover TRAW, Brandon Folkes of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #402). Their current call is Neutral with a $1.00 target.
What is Traws Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.29 per share (range $-0.29 – $-0.29) across 1 analysts. Full-year EPS is projected at $-1.33, rising to $-1.88 the following year.
How much revenue is Traws Pharma Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading TRAW lately?+
As of Nov 18, 2026, 0 of 2 active firms rate TRAW a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their TRAW calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.